CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS

摘要

This invention relates to a novel class of heterocyclic compounds that bind chemokine receptors, inhibitng the binding of their natural ligands thereby. These compounds result in protective effects against infection by HIV throug h binding to chemokine receptors, including CXCR4 and CCR5, thus inhibiting th e subsequent binding by these chemokines. The present invention provides a compound of Formula (I) wherein, W is a nitrogen atom and Y is absent or, W is a carbon atom and Y=H; R1 to R7 may be the same or different and are independently selected from hydrogen or straight, branched or cyclic C1-6 alkyl; R8 is a substituted heterocyclic group or a substituted aromatic grou p Ar is an aromatic or heteroaromatic ring each optionally substituted at sing le or multiple, non-linking positions with electron-donating or withdrawing groups; n and n' are independently, 0-2; X is a group of formulae (a) or (b) wherein, Ring A is an optionally substituted, saturated or unsaturated 5 or 6- membered ring, and P is an optionally substituted carbon atom, an optionally substituted nitrogen atom, sulfur or oxygen atom. Ring B is an optionally substituted 5 to 7-membered ring. Ring A and Ring B in the above formula can be connected to the group W from any position via the group V, wherein V is a chemical bond,a (CH2)n'' group (where n''=0-2) or a C=O group. Z is, (1) a hydrogen atom, (2) an optionally substituted C1-6 alkyl group, (3) a C0-6 alkyl group substitued with an optionally substituted aromatic or heterocycl ic group, (4) an optionally substituted C0-6 alkylamino or C3-7 cycloalkylamino group, (5) an optionally substituted carbonyl group or sulfonyl. These compounds further include any pharmaceutically acceptable acid addition salt s and metal complexes thereof and any stereoisomeric forms and mixtures of stereoisomeric forms thereof.